Jonah David Garry

Jonah David Garry

Auto-generated profile, based on publicly available information

Jonah David Garry

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
AMAmanda M. Morrison
Amanda M. Morrison
SHShi Huang
Shi Huang
JAJeffrey S. Annis
Jeffrey S. Annis
JGJonah D. Garry
Jonah D. Garry
AHAnna R. Hemnes
Anna R. Hemnes
EBEvan L. Brittain
Evan L. Brittain
Background: Pulmonary hypertension and right ventricular (RV) dysfunction are drivers of adverse outcomes; however, modifiable risk factors for RV dysfunction are not well described. We investigated the association between clinical markers of metabolic syndrome and echocardiographic RV function in a large referral population. Methods and Results: Using electronic health record data, we performed a retrospective cohort study of patients aged ≥18 years referred for transthoracic echocardiography between 2010 and 2020 with RV systolic pressure (RVSP) or tricuspid annular plane systolic excursion (TAPSE) values. Pulmonary hypertension was defined by RVSP >33 mm Hg and RV dysfunction by TAPSE ≤1.8 cm. Our sample included 37 203 patients of whom 19 495 (52%) were women, 29 752 (83%) were White, with a median age of 63 years (interquartile range, 51–73). Median (interquartile range) RVSP was 30.0 mm Hg (24.0–38.7), and median TAPSE was 2.1 cm (1.7–2.4). Within our sample, 40% had recorded RVSP >33 mm Hg, and 32% with TAPSE <1.8 cm. Increase in RVSP from normal (39 mm Hg) was associated with lower low‐density lipoprotein and high‐density lipoprotein, and higher hemoglobin A1c and body mass index ( P 1.8 cm, TAPSE 1.5–1.8 cm, and TAPSE <1.5 cm was associated with increased triglyceride:high‐density lipoprotein ratio and hemoglobin A1c, and decreased body mass index, low‐density lipoprotein, high‐density lipoprotein, and systolic blood pressure ( P <0.001). Most associations between cardiometabolic predictors and RVSP and TAPSE were nonlinear with clear inflection points associated with higher pulmonary pressure and lower RV function. Conclusions: Clinical measures of cardiometabolic function were highly associated with echocardiographic measures of right ventricular function and pressure.

28 August 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JGJonah D. Garry
Jonah D. Garry
NKNicholas A. Kolaitis
Nicholas A. Kolaitis
RKRichard Kronmal
Richard Kronmal
TTThenappan Thenappan
Thenappan Thenappan
AHAnna Hemnes
Anna Hemnes
TMTeresa De Marco
Teresa De Marco

23 May 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JGJonah D. Garry
Jonah D. Garry
ATAnjali B. Thakkar
Anjali B. Thakkar
MDMatthew S. Durstenfeld
Matthew S. Durstenfeld
YMYifei Ma
Yifei Ma
SWSithu Win
Sithu Win
PHPriscilla Y. Hsue
Priscilla Y. Hsue

22 May 2026 in Circulation Research
Verified
Journal Article
Closed access
JCJonathan Chacon-Barahona
Jonathan Chacon-Barahona
SCSamuel J. Chung
Samuel J. Chung
JGJonah D. Garry
Jonah D. Garry
RFRobert P. Frantz
Robert P. Frantz
FRFranz Rischard
Franz Rischard
EHEvelyn M. Horn
Evelyn M. Horn
BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.

16 April 2025 in Pulmonary Circulation
Verified
Journal Article
Open access
AHAndrew M. Hughes
Andrew M. Hughes
ALAlisha Lindsey
Alisha Lindsey
JAJeffrey Annis
Jeffrey Annis
KBKelly Burke
Kelly Burke
HMHiral Master
Hiral Master
EBEvan L. Brittain
Evan L. Brittain
Reduced functional capacity and poor sleep quality are common in pulmonary arterial hypertension (PAH). Wearable devices are an emerging, user‐friendly tool to capture activity and sleep information. We aimed to determine whether Fitbit‐derived activity and sleep trends provide clinically meaningful information in patients with PAH. Our prospective observational study recruited patients with PAH from across the United States using remote enrollment strategies and in‐person efforts. Participants wore a Fitbit device for 12 weeks at baseline and a subgroup with 1‐year follow‐up. A matched control cohort was generated from the All of Us Research Program and we evaluated changes in patients with PAH compared to matched controls. Among 110 patients with baseline monitoring, average daily steps correlated with 6MWD (r = 0.61, p < 0.001) and percent rapid eye movement (REM) sleep (r = 0.28, p = 0.008). In 44 PAH participants who completed baseline and 1‐year monitoring, there was a group‐time interaction for percent light sleep (p = 0.024) and percent REM sleep (p = 0.034), which demonstrated that sleep quality worsened in patients with PAH over 1 year compared to matched controls. Average daily steps decreased in patients with PAH from 5200 [IQR 3212–7458] at baseline to 4651 [IQR 2912–6827] at 1 year (p = 0.008). In conclusion, our study demonstrated the potential clinical value of wearable devices by showing that activity and sleep quality are reduced in PAH compared to matched controls and these measures decline over time. Future studies should investigate if monitoring these health behaviors detects early functional decline and whether targeted interventions may improve outcomes.

1 May 2025 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
JGJonah D. Garry
Jonah D. Garry
SKSuman Kundu
Suman Kundu
JAJeffrey Annis
Jeffrey Annis
CAChuck Alcorn
Chuck Alcorn
SESvetlana Eden
Svetlana Eden
EBEvan L. Brittain
Evan L. Brittain
Rationale: Incidence rates for pulmonary hypertension using diagnostic data in patients with cardiopulmonary disease are not known. Objectives: To determine incidence rates of, risk factors for, and mortality hazard associated with pulmonary hypertension among patients referred for transthoracic echocardiography. Methods: A retrospective cohort study was conducted using data from the U.S. Department of Veterans Affairs (VA) (1999–2020) and Vanderbilt University Medical Center (1994–2020). Pulmonary hypertension was defined as pulmonary artery systolic pressure >35 mm Hg, with prevalent cases excluded. Heart failure and chronic obstructive pulmonary disease were the primary exposures of interest. The primary outcome was incident pulmonary hypertension. Secondarily, we examined mortality rate after incident diagnosis. Results: We identified 245,067 VA patients (94% men, 20% Black) and 117,526 Vanderbilt patients (46% men, 11% Black) without pulmonary hypertension, of whom 38,882 VA patients and 8,061 Vanderbilt patients developed pulmonary hypertension. Only 18–19% of patients with echocardiography-based pulmonary hypertension also had diagnostic codes. The hazard of pulmonary hypertension was fourfold higher in patients with heart failure and chronic obstructive pulmonary disease compared with patients without either. Mortality rates increased from pulmonary artery systolic pressure of 35–45 mm Hg and then plateaued. Independent risk factors for incident pulmonary hypertension included older age, male sex, Black race, and cardiometabolic comorbidities. Conclusions: Pulmonary hypertension incidence rates estimated by diagnostic data are higher than code-based rates. Heart failure and chronic obstructive pulmonary disease strongly associate with incident pulmonary hypertension. Pulmonary artery systolic pressure >45 mm Hg at diagnosis is associated with high mortality. New pulmonary hypertension on echocardiography is an important prognostic sign.